EGFR 타깃 프로그램 | 바이오모아

Data Tier

ADC · Antibody · CGT를 FDA 승인, ORR·PASI·ACR·BCVA, 임상 등록 규모, Phase 3, 조회수 등 공개 데이터로 복합 점수화합니다. S–C 티어와 가점 요인은 규칙 기반(Data Tier)이며 LLM이 아닙니다.

RSS 구독 차세대 추천

A Tier1개

강한 임상/승인 신호, 주요 경쟁 후보

Tier	프로그램	Modality	점수	가점 요인	요약	분석
A	EGFR inhibitor (Cetuximab) Eli Lilly · EGFR	Antibody	70	ORR 70.6%PFS 데이터OS 보고임상 166건등록 23,132명	Antibody — ORR 70.6% · PFS 데이터 · OS 보고	Antibody Phase 2에서 효능·안전성을 검증하는 단계입니다. 보고된 ORR 70.6%는 동일 EGFR·Advanced Solid Tumor; NS군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 23,132명 규모.

A70점

EGFR inhibitor

Antibody · Eli Lilly · EGFR

Antibody — ORR 70.6% · PFS 데이터 · OS 보고

ORR 70.6% · PFS 데이터 · OS 보고 · 임상 166건

Antibody Phase 2에서 효능·안전성을 검증하는 단계입니다. 보고된 ORR 70.6%는 동일 EGFR·Advanced Solid Tumor; NS군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 23,132명 규모.

프로그램 (52)

CGTBiologicstaleJuno Therapeutics, Inc., a Bris…Phase 1

EGFRt/19-28z/4-1BBL CAR T cells (EGFRt/19-28z/4-1BBL CAR T cells)

Chronic Lymphocytic Leukemia (CLL); Relapsed · EGFR

EGFR 타깃

Data Tier

프로그램 (52)

EGFRt/19-28z/4-1BBL CAR T cells (EGFRt/19-28z/4-1BBL CAR T cells)

CART-EGFR-IL13Ra2 T cells (CART-EGFR-IL13Ra2 T cells)

anti-EGFR CAR T (anti-EGFR CAR T)

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

EGFRt/19-28z/IL-12 CAR T-lymphocytes (EGFRt/19-28z/IL-12 CAR T-lymphocytes)

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

pembrolizumab (Keytruda, Pembrolizumab, pemetrexed, platinum)

IMGN289 (IMGN289)

Panitumumab or Cetuximab (Anti-EGFR, Anti-EGFR (Panitumumab or Cetuximab))

HWK-007 (HWK-007)

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

EGFRvIII-CARs (EGFRvIII-CARs)

CART-EGFRvIII T cells (CART-EGFRvIII T cells)

SCRI-E2CAR_EGFRtv1 (SCRI-E2CAR_EGFRtv1)

EGFRt/BCMA-41BBz CAR T cell (EGFRt/BCMA-41BBz CAR T cell)

Metabolically Armed EGFRvIII CAR-T cells (Metabolically Armed EGFRvIII CAR-T cells)

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

CART-EGFR (CART-EGFR)

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

EGFRvIII CAR T cells (EGFRvIII CAR T cells)

EGFR 타깃

Data Tier

프로그램 (52)

EGFRt/19-28z/4-1BBL CAR T cells (EGFRt/19-28z/4-1BBL CAR T cells)

CART-EGFR-IL13Ra2 T cells (CART-EGFR-IL13Ra2 T cells)

anti-EGFR CAR T (anti-EGFR CAR T)

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

EGFRt/19-28z/IL-12 CAR T-lymphocytes (EGFRt/19-28z/IL-12 CAR T-lymphocytes)

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

pembrolizumab (Keytruda, Pembrolizumab, pemetrexed, platinum)

IMGN289 (IMGN289)

Panitumumab or Cetuximab (Anti-EGFR, Anti-EGFR (Panitumumab or Cetuximab))

HWK-007 (HWK-007)

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

EGFRvIII-CARs (EGFRvIII-CARs)

CART-EGFRvIII T cells (CART-EGFRvIII T cells)

SCRI-E2CAR_EGFRtv1 (SCRI-E2CAR_EGFRtv1)

EGFRt/BCMA-41BBz CAR T cell (EGFRt/BCMA-41BBz CAR T cell)

Metabolically Armed EGFRvIII CAR-T cells (Metabolically Armed EGFRvIII CAR-T cells)

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

CART-EGFR (CART-EGFR)

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

EGFRvIII CAR T cells (EGFRvIII CAR T cells)

EGFR 타깃

Data Tier

프로그램 (52)

EGFRt/19-28z/4-1BBL CAR T cells (EGFRt/19-28z/4-1BBL CAR T cells)

CART-EGFR-IL13Ra2 T cells (CART-EGFR-IL13Ra2 T cells)

anti-EGFR CAR T (anti-EGFR CAR T)

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

EGFRt/19-28z/IL-12 CAR T-lymphocytes (EGFRt/19-28z/IL-12 CAR T-lymphocytes)

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

pembrolizumab (Keytruda, Pembrolizumab, pemetrexed, platinum)

IMGN289 (IMGN289)

Panitumumab or Cetuximab (Anti-EGFR, Anti-EGFR (Panitumumab or Cetuximab))

HWK-007 (HWK-007)

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

EGFRvIII-CARs (EGFRvIII-CARs)

CART-EGFRvIII T cells (CART-EGFRvIII T cells)

SCRI-E2CAR_EGFRtv1 (SCRI-E2CAR_EGFRtv1)

EGFRt/BCMA-41BBz CAR T cell (EGFRt/BCMA-41BBz CAR T cell)

Metabolically Armed EGFRvIII CAR-T cells (Metabolically Armed EGFRvIII CAR-T cells)

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

CART-EGFR (CART-EGFR)

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

EGFRvIII CAR T cells (EGFRvIII CAR T cells)